JP2019537589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537589A5 JP2019537589A5 JP2019522974A JP2019522974A JP2019537589A5 JP 2019537589 A5 JP2019537589 A5 JP 2019537589A5 JP 2019522974 A JP2019522974 A JP 2019522974A JP 2019522974 A JP2019522974 A JP 2019522974A JP 2019537589 A5 JP2019537589 A5 JP 2019537589A5
- Authority
- JP
- Japan
- Prior art keywords
- preparation according
- capsaicin
- polyethylene glycol
- solubilizer
- polyethylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 134
- 238000002360 preparation method Methods 0.000 claims description 129
- 229960002504 capsaicin Drugs 0.000 claims description 65
- 235000017663 capsaicin Nutrition 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 49
- -1 polyethylene Polymers 0.000 claims description 47
- 239000002202 Polyethylene glycol Substances 0.000 claims description 46
- 229920001223 polyethylene glycol Polymers 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 46
- 239000004698 Polyethylene Substances 0.000 claims description 40
- 229920000573 polyethylene Polymers 0.000 claims description 40
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims description 38
- 238000009472 formulation Methods 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 208000002193 Pain Diseases 0.000 claims description 15
- 230000003204 osmotic effect Effects 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 239000003963 antioxidant agent Substances 0.000 claims description 12
- 239000002738 chelating agent Substances 0.000 claims description 12
- 239000007972 injectable composition Substances 0.000 claims description 12
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical group CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 10
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 239000003607 modifier Substances 0.000 claims description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 6
- 208000006820 Arthralgia Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 210000000629 knee joint Anatomy 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 2
- 150000002989 phenols Chemical class 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 210000003797 carpal joint Anatomy 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 description 1
- 229960002860 zucapsaicin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416345P | 2016-11-02 | 2016-11-02 | |
| US62/416,345 | 2016-11-02 | ||
| PCT/US2017/059628 WO2018085476A1 (en) | 2016-11-02 | 2017-11-02 | Stable aqueous capsaicin injectable formulations and medical uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019537589A JP2019537589A (ja) | 2019-12-26 |
| JP2019537589A5 true JP2019537589A5 (enExample) | 2020-12-10 |
| JP7100635B2 JP7100635B2 (ja) | 2022-07-13 |
Family
ID=62077165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522974A Active JP7100635B2 (ja) | 2016-11-02 | 2017-11-02 | 安定な水性カプサイシン注射製剤およびその医学的使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US11000490B2 (enExample) |
| EP (1) | EP3534961B1 (enExample) |
| JP (1) | JP7100635B2 (enExample) |
| KR (1) | KR102657458B1 (enExample) |
| CN (1) | CN110035740B (enExample) |
| AU (1) | AU2017353782B2 (enExample) |
| CA (1) | CA3041121A1 (enExample) |
| ES (1) | ES3066533T3 (enExample) |
| IL (1) | IL266279B2 (enExample) |
| MX (1) | MX2019005202A (enExample) |
| NZ (1) | NZ752750A (enExample) |
| WO (1) | WO2018085476A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11000490B2 (en) | 2016-11-02 | 2021-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
| WO2019018769A1 (en) | 2017-07-20 | 2019-01-24 | Centrexion Therapeutics Corporation | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE |
| EP3840739B1 (en) * | 2018-08-24 | 2025-11-12 | Centrexion Therapeutics Corporation | Capsaicin sequential dosing method for treatment of knee joint pain |
| MX2021013934A (es) | 2020-04-05 | 2021-12-15 | Pfizer | Compuestos y metodos para el tratamiento de covid-19. |
| CN113855626B (zh) * | 2020-08-07 | 2023-03-24 | 北京泰德制药股份有限公司 | 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法 |
| TR2021013305A2 (tr) * | 2021-08-23 | 2023-03-21 | Tuem Ekip Ilac Anonim Sirketi | Li̇yofi̇li̇ze levosi̇mendan formülasyonlari |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599342A (en) | 1984-01-16 | 1986-07-08 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
| US5099030A (en) | 1987-03-09 | 1992-03-24 | The Procter & Gamble Company | Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain |
| US5021450A (en) | 1989-05-30 | 1991-06-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
| US5431914A (en) | 1992-04-17 | 1995-07-11 | Adekunle; Michael | Method of treating an internal condition by external application of capsaicin without the need for systemic absorption |
| US5985860A (en) | 1992-06-03 | 1999-11-16 | Toppo; Frank | System for transdermal delivery of pain relieving substances |
| US5318960A (en) | 1992-06-03 | 1994-06-07 | Frank Toppo | System for transdermal delivery of pain relieving substances |
| DE59408028D1 (de) | 1993-09-30 | 1999-05-06 | Medichemie Ag | Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie |
| US6248788B1 (en) | 1996-11-06 | 2001-06-19 | The Regents Of The University Of California | Therapeutic method with capsaicin and capasicin analogs |
| WO1998020867A1 (en) | 1996-11-15 | 1998-05-22 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists |
| US6060060A (en) | 1997-01-31 | 2000-05-09 | Bmb Patent Holding Corporation | Analgesic compositions from sweet peppers and methods of use thereof |
| EP1201241B8 (en) | 1997-03-13 | 2010-10-27 | James N. Campbell | Compositions containing capsaicin or capsaicin analogues and an anesthetic |
| JP2002514221A (ja) | 1997-05-27 | 2002-05-14 | アルゴス ファーマシューティカル コーポレーション | カプサイシノイド及びその強化薬を含有する鎮痛薬組成物 |
| US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
| CA2442049C (en) | 2001-03-22 | 2010-06-01 | Michael J. Iadarola | Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist |
| US20030104085A1 (en) | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
| WO2004009064A1 (de) | 2002-07-19 | 2004-01-29 | Mestex Ag | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
| NZ540769A (en) | 2002-12-18 | 2009-03-31 | Algorx Pharmaceuticals Inc | Administration of capsaicinoids for the treatment of pain |
| WO2004056305A2 (en) | 2002-12-18 | 2004-07-08 | Algorx | Administration of capsaicinoids |
| US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
| EP2311437A1 (en) | 2003-12-19 | 2011-04-20 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| CN101119713A (zh) * | 2004-11-24 | 2008-02-06 | 阿尔高克斯制药公司 | 类辣椒素凝胶制剂及其用途 |
| WO2006066419A1 (de) | 2004-12-22 | 2006-06-29 | Mestex Ag | Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels |
| EP1838301B1 (de) | 2004-12-28 | 2015-01-28 | Mestex AG | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen |
| ES2384244T3 (es) | 2004-12-28 | 2012-07-02 | Mestex Ag | Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco |
| US20080160487A1 (en) | 2006-12-29 | 2008-07-03 | Fairfield Language Technologies | Modularized computer-aided language learning method and system |
| US8222564B2 (en) | 2008-02-13 | 2012-07-17 | Tyco Healthcare Group, Lp | Methods of altering surgical fiber |
| US8158682B2 (en) | 2008-09-12 | 2012-04-17 | Vallinex, Inc. | Instillation administration of capsaicinoids for the treatment of pain |
| MX2011002688A (es) | 2008-09-12 | 2011-04-12 | Critical Pharmaceuticals Ltd | Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel. |
| CN101507818B (zh) | 2008-12-15 | 2010-11-10 | 中国人民武装警察部队医学院 | 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶 |
| US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| US20130303495A1 (en) | 2009-12-31 | 2013-11-14 | Sov Therapeutics | Emulsion formulations |
| WO2012134943A1 (en) | 2011-03-25 | 2012-10-04 | Abbott Laboratories | Trpv1 antagonists |
| KR101769010B1 (ko) | 2011-09-09 | 2017-08-17 | 비쭈리 헬스 사이언스 엘엘씨 | Trpv1 선택적 작용제를 포함하는 통증 완화 조성물, 및 이의 제조방법 및 용도 |
| WO2013158814A1 (en) | 2012-04-18 | 2013-10-24 | Mallinckrodt Llc | Immediate release, abuse deterrent pharmaceutical compositions |
| EP2838536B1 (en) | 2012-04-18 | 2017-08-09 | Mallinckrodt LLC | Immediate release pharmaceutical compositions with abuse deterrent properties |
| GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
| US11154535B2 (en) | 2012-07-31 | 2021-10-26 | Egis Pharmaceuticals Plc | Transdermal formulation containing COX inhibitors |
| US20150190509A1 (en) | 2012-08-03 | 2015-07-09 | Mestex Ag | Resiniferatoxin solution |
| US20140142073A1 (en) * | 2012-11-12 | 2014-05-22 | Api Genesis, Llc | Aqueous based capsaicinoid formulations and methods of manufacture and use |
| GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
| US11351139B2 (en) * | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
| GB201317756D0 (en) | 2013-10-08 | 2013-11-20 | Critical Pharmaceuticals Ltd | New process |
| GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| GB201319792D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
| US20150133561A1 (en) | 2013-11-12 | 2015-05-14 | Vizuri Health Sciences Llc | Aqueous based capsaicinoid formulations and methods of manufacture and use |
| ES2838756T3 (es) | 2014-01-24 | 2021-07-02 | Sentiss Pharma Private Ltd | Composición farmacéutica que comprende brinzolamida |
| WO2015160842A1 (en) * | 2014-04-14 | 2015-10-22 | Flex Pharma, Inc. | Methods and formulatiions of capsaicinoids and capsinoids |
| MX2016013486A (es) | 2014-04-14 | 2017-05-10 | Flex Pharma Inc | Activadores de canales ionicos y metodos de uso. |
| KR102073258B1 (ko) | 2014-04-15 | 2020-02-04 | 비쭈리 헬스 사이언스 엘엘씨 | 통증 완화용 국소 조성물, 제조방법 및 용도 |
| CN105030760B (zh) | 2014-04-24 | 2018-10-02 | 长弘生物科技股份有限公司 | 稳定医药组合物 |
| EA033046B1 (ru) | 2014-06-25 | 2019-08-30 | НУКАНА ПиЭлСи | Состав, содержащий пролекарство гемцитабина |
| US10736842B2 (en) | 2014-06-25 | 2020-08-11 | Synergia Bio Sciences Private Limited | Pharmaceutical oil-in-water nano-emulsion |
| EP3182968A4 (en) | 2014-08-19 | 2018-05-09 | Muzari, Mandishora Israel | Capsaicinoids and uses thereof as medicaments |
| US20180311189A1 (en) | 2014-11-13 | 2018-11-01 | Centrexion Therapeutics Corporation | Capsaicinoids for Use in Treating ACRAL Lick Granuloma |
| US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| US20180021286A1 (en) | 2015-02-02 | 2018-01-25 | Enspire Group LLC | Stabilized dialkyl fumarate compositions |
| CA2987517A1 (en) | 2015-05-29 | 2016-12-08 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition of isotretinoin |
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| US20200261409A1 (en) | 2015-11-20 | 2020-08-20 | Sorrento Therapeutics, Inc. | Methods for pain treatment using resiniferatoxin |
| US9989978B2 (en) | 2016-01-21 | 2018-06-05 | Itt Manufacturing Enterprises Llc | Natural gas pressure regulator having adjustable valve seat |
| US20190022036A1 (en) | 2016-01-22 | 2019-01-24 | Centrexion Therapeutics Corporation | Capsaicin sequential dosing method for treatment of morton's neuroma pain |
| US10851123B2 (en) | 2016-02-23 | 2020-12-01 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| CA3025268A1 (en) | 2016-05-25 | 2017-11-30 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
| US11000490B2 (en) | 2016-11-02 | 2021-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
| WO2018217937A1 (en) | 2017-05-24 | 2018-11-29 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
-
2017
- 2017-11-02 US US16/342,652 patent/US11000490B2/en active Active
- 2017-11-02 CA CA3041121A patent/CA3041121A1/en active Pending
- 2017-11-02 JP JP2019522974A patent/JP7100635B2/ja active Active
- 2017-11-02 WO PCT/US2017/059628 patent/WO2018085476A1/en not_active Ceased
- 2017-11-02 CN CN201780075307.XA patent/CN110035740B/zh active Active
- 2017-11-02 ES ES17868308T patent/ES3066533T3/es active Active
- 2017-11-02 MX MX2019005202A patent/MX2019005202A/es unknown
- 2017-11-02 NZ NZ752750A patent/NZ752750A/en unknown
- 2017-11-02 KR KR1020197015747A patent/KR102657458B1/ko active Active
- 2017-11-02 EP EP17868308.2A patent/EP3534961B1/en active Active
- 2017-11-02 AU AU2017353782A patent/AU2017353782B2/en active Active
-
2019
- 2019-04-28 IL IL266279A patent/IL266279B2/en unknown
- 2019-05-01 US US16/400,278 patent/US10493047B2/en active Active
- 2019-11-26 US US16/695,824 patent/US10772853B2/en active Active
- 2019-11-26 US US16/695,831 patent/US10765649B2/en active Active
-
2020
- 2020-09-11 US US17/018,148 patent/US11344516B2/en active Active
-
2022
- 2022-03-22 US US17/701,160 patent/US11992470B2/en active Active
-
2024
- 2024-05-24 US US18/674,288 patent/US20240423931A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2336034T3 (es) | Composiciones de diclofenaco inyectables estables. | |
| RU2016139373A (ru) | Растворы бупренорфина с замедленным высвобождением | |
| KR20180001587A (ko) | 안정화된 안과용 갈락토만난 제제 | |
| CN107810000B (zh) | 来氟米林的可注射药物组合物 | |
| US20150051168A1 (en) | Stable liquid pharmaceutical composition containing piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt and the manufacturing method thereof | |
| JP2020527574A5 (enExample) | ||
| RU2011136694A (ru) | КОМПЛЕКС ПЕПТИДА-ИНГИБИТОРА TGF-β1 И ЦИКЛОДЕКСТРИНА ИЛИ ЕГО ПРОИЗВОДНОГО, ЭМУЛЬСИЯ ПЕПТИДА-ИНГИБИТОРА TGF-β1, ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ ВЫШЕУКАЗАННЫХ КОМПЛЕКСА И ЭМУЛЬСИИ, ПРОДУКТ, ПОЛУЧЕННЫЙ ВЫШЕУПОМЯНУТЫМИ СПОСОБАМИ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ И/ИЛИ СОСТОЯНИЯ, ОПОСРЕДОВАННОГО TGF-β1 | |
| KR20190101368A (ko) | 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도 | |
| JP5759720B2 (ja) | 濃縮エスモロール | |
| WO2018073269A1 (en) | Liquid formulations of daptomycin | |
| JP5872551B2 (ja) | パラセタモールを含む医薬組成物およびその製造法 | |
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| CN101677943B (zh) | 使用苯甲醇的多剂量浓缩艾司洛尔 | |
| RU2008126108A (ru) | Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту | |
| TWI649097B (zh) | 乙醯胺酚之可注射製劑 | |
| JP2024522892A (ja) | 薬学的組成物 | |
| KR102387287B1 (ko) | 안정한 이부프로펜 주사용 조성물 | |
| JP2009538822A5 (enExample) | ||
| WO2026105164A1 (en) | Non-aqueous liquid formulations of tetracycline antibiotics | |
| RU2020115819A (ru) | Фармацевтические составы, содержащие агонист опиоидных рецепторов в качестве активного ингредиента, способы их получения и их терапевтическое применение | |
| JP2014528477A5 (ja) | 急性腎臓損傷を治療するための組成物及び溶液 | |
| TR201902890A2 (tr) | İbuprofen İçeren Enjektabl Çözelti Formunda Yeni Bir Farmasötik Kompozisyon | |
| WO2020025986A1 (en) | Injectable combination of diclofenac sodium and thiocolchicoside |